2024-519890-21-00
Not yet recruiting
Phase III and phase IV (Integrated)
PROSPECTIVE RANDOMISED CLINICAL TRIAL TO EVALUATE THE EARLY RECURRENCE RATE IN NON-MUSCLE INVASIVE BLADDER CANCER BETWEEN THE USE OF CHEMOHYPERTHERMIA (QH) WITH MITOMYCIN-C PRIOR TO TRANSURETHRAL BLADDER RESECTION IN A MAJOR OUTPATIENT SURGERY PROGRAMME AND TREATMENT WITH MITOMYCIN-C IN NORMOTHERMIA POST-RESECTION.
University Hospital Of Canary Islands1 site in 1 country152 target enrollmentStarted: November 28, 2024Last updated:
Overview
- Phase
- Phase III and phase IV (Integrated)
- Status
- Not yet recruiting
- Sponsor
- University Hospital Of Canary Islands
- Enrollment
- 152
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Ana Plata Bello
Scientific
University Hospital Of Canary Islands
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT2024-519010-31-00Fondazione Melanoma Onlus80
Recruiting
Not Applicable
Versius Gynecology StudyNCT07289295CMR Surgical Ltd45
Recruiting
Phase 1
clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee2024-514833-39-00Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz60
Not yet recruiting
Not Applicable
AAR/AAR+HAR vs AAR+TAR+FET for Type A Aortic Intramural HematomaAortic Intramural HematomaNCT07272655Second Hospital of Jilin University400
Not yet recruiting
Phase 1
Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers.2025-523146-27-00Innovative Molecules GmbH30